MicroRNA-185-5p restores glucocorticoid sensitivity by suppressing the mammalian target of rapamycin complex (mTORC) signaling pathway to enhance glucocorticoid receptor autoregulation

References

• Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013;381:1943–1955.
   PubMed Web of Science ®Google Scholar
• Gaynon PS, Carrel AL. Glucocorticosteroid therapy in childhood acute lymphoblastic leukemia. Adv Exp Med Biol. 1999;457:593–605.
   PubMed Web of Science ®Google Scholar
• Quddus FF, Leventhal BG, Boyett JM, et al. Glucocorticoid receptors in immunological subtypes of childhood acute lymphocytic leukemia cells: a Pediatric Oncology Group Study. Cancer Res. 1985;45:6482–6486.
   PubMed Web of Science ®Google Scholar
• Riehm H, Reiter A, Schrappe M, et al. Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83). Klin Padiatr. 1987;199:151–160.
   PubMed Web of Science ®Google Scholar
• Dordelmann M, Reiter A, Borkhardt A, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood. 1999;94:1209–1217.
   PubMed Web of Science ®Google Scholar
• Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia. 2000;14:2205–2222.
   PubMed Web of Science ®Google Scholar
• Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111:4477–4489.
   PubMed Web of Science ®Google Scholar
• Bhadri VA, Trahair TN, Lock RB. Glucocorticoid resistance in paediatric acute lymphoblastic leukaemia. J Paediatr Child Health. 2012;48:634–640.
   PubMed Web of Science ®Google Scholar
• Gross KL, Lu NZ, Cidlowski JA. Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Mol Cell Endocrinol. 2009;300:7–16.
   PubMed Web of Science ®Google Scholar
• Nicolaides NC, Roberts ML, Kino T, et al. A novel point mutation of the human glucocorticoid receptor gene causes primary generalized glucocorticoid resistance through impaired interaction with the LXXLL motif of the p160 coactivators: dissociation of the transactivating and transreppressive activities. J Clin Endocrinol Metab. 2014;99:E902–90E907.
   PubMed Web of Science ®Google Scholar
• Nicolaides N, Lamprokostopoulou A, Sertedaki A, et al. Recent advances in the molecular mechanisms causing primary generalized glucocorticoid resistance. Hormones (Athens). 2016;15:23–34.
   PubMedGoogle Scholar
• Nicolaides NC, Charmandari E, Chrousos GP, et al. Recent advances in the molecular mechanisms determining tissue sensitivity to glucocorticoids: novel mutations, circadian rhythm and ligand-induced repression of the human glucocorticoid receptor. BMC Endocr Disord. 2014;14:71.
   PubMed Web of Science ®Google Scholar
• Sun X, Fang M, Guan Y, et al. Changes of glucocorticoid receptor isoforms expression in acute lymphoblastic leukemia correlate with glucocorticoid resistance. Pharmazie. 2015;70:316–321.
   PubMed Web of Science ®Google Scholar
• Chen P, Jiang T, Ouyang J, et al. Glucocorticoid receptor auto-upregulation and its relation with glucocorticoid sensitivity in idiopathic nephrotic syndrome. Int Urol Nephrol. 2011;43:167–174.
   PubMed Web of Science ®Google Scholar
• Rainer J, Ploner C, Jesacher S, et al. Glucocorticoid-regulated microRNAs and mirtrons in acute lymphoblastic leukemia. Leukemia. 2009;23:746–752.
   PubMed Web of Science ®Google Scholar
• Lovat F, Fassan M, Gasparini P, et al. miR-15b/16-2 deletion promotes B-cell malignancies. Proc Natl Acad Sci USA. 2015;112:11636–11641.
   PubMed Web of Science ®Google Scholar
• Uchida S, Nishida A, Hara K, et al. Characterization of the vulnerability to repeated stress in Fischer 344 rats: possible involvement of microRNA-mediated down-regulation of the glucocorticoid receptor. Eur J Neurosci. 2008;27:2250–2261.
   PubMed Web of Science ®Google Scholar
• Vreugdenhil E, Verissimo CS, Mariman R, et al. MicroRNA 18 and 124a down-regulate the glucocorticoid receptor: implications for glucocorticoid responsiveness in the brain. Endocrinology. 2009;150:2220–2228.
   PubMed Web of Science ®Google Scholar
• Alqurashi N, Hashimi SM, Wei MQ. Chemical inhibitors and microRNAs (miRNA) targeting the mammalian target of rapamycin (mTOR) pathway: potential for novel anticancer therapeutics. IJMS. 2013;14:3874–3900.
   Web of Science ®Google Scholar
• Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell.2006;124:471–484.
   PubMed Web of Science ®Google Scholar
• Teachey DT, Grupp SA, Brown VI. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol. 2009;145:569–580.
   PubMed Web of Science ®Google Scholar
• Yan H, Frost P, Shi Y, et al. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Res. 2006;66:2305–2313.
   PubMed Web of Science ®Google Scholar
• Jundt F, Raetzel N, Muller C, et al. A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. Blood. 2005;106:1801–1807.
   PubMed Web of Science ®Google Scholar
• Stromberg T, Dimberg A, Hammarberg A, et al. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood. 2004;103:3138–3147.
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274–293.
   PubMed Web of Science ®Google Scholar
• Tessel MA, Benham AL, Krett NL, et al. Role for microRNAs in regulating glucocorticoid response and resistance in multiple myeloma. Horm Cancer. 2011;2:182–189.
   PubMedGoogle Scholar
• Wang X, Li C, Ju S, et al. Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation. Leuk Lymphoma. 2011;52:1991–1998.
   PubMed Web of Science ®Google Scholar
• Beesley AH, Firth MJ, Ford J, et al. Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism. Br J Cancer. 2009;100:1926–1936.
   PubMed Web of Science ®Google Scholar
• Martelli AM, Evangelisti C, Chappell W, et al. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia. 2011;25:1064–1079.
   PubMed Web of Science ®Google Scholar
• Park S, Chapuis N, Tamburini J, et al. Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica. 2010;95:819–828.
   PubMed Web of Science ®Google Scholar
• Recher C, Dos Santos C, Demur C, et al. mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle. 2005;4:1540–1549.
   PubMed Web of Science ®Google Scholar
• Singh Y, Garden OA, Lang F, et al. MicroRNA-15b/16 enhances the induction of regulatory T cells by regulating the expression of Rictor and mTOR. J Immunol. 2015;195:5667–5677.
   PubMed Web of Science ®Google Scholar
• Lauten M, Cario G, Asgedom G, et al. Protein expression of the glucocorticoid receptor in childhood acute lymphoblastic leukemia. Haematologica. 2003;88:1253–1258.
   PubMed Web of Science ®Google Scholar
• Ramdas J, Liu W, Harmon JM. Glucocorticoid-induced cell death requires autoinduction of glucocorticoid receptor expression in human leukemic T cells. Cancer Res. 1999;59:1378–1385.
   PubMed Web of Science ®Google Scholar
• Kofler R, Schmidt S, Kofler A, et al. Resistance to glucocorticoid-induced apoptosis in lymphoblastic leukemia. J Endocrinol. 2003;178:19–27.
   PubMed Web of Science ®Google Scholar
• Obexer P, Certa U, Kofler R, et al. Expression profiling of glucocorticoid-treated T-ALL cell lines: rapid repression of multiple genes involved in RNA-, protein- and nucleotide synthesis. Oncogene. 2001;20:4324–4336.
   PubMed Web of Science ®Google Scholar
• Tonko M, Ausserlechner MJ, Bernhard D, et al. Gene expression profiles of proliferating vs. G1/G0 arrested human leukemia cells suggest a mechanism for glucocorticoid-induced apoptosis. FASEB J. 2001;15:693–699.
   PubMed Web of Science ®Google Scholar
• Riml S, Schmidt S, Ausserlechner MJ, et al. Glucocorticoid receptor heterozygosity combined with lack of receptor auto-induction causes glucocorticoid resistance in Jurkat acute lymphoblastic leukemia cells. Cell Death Differ. 2004;11:S65–S72.
   PubMed Web of Science ®Google Scholar
• Eisen LP, Elsasser MS, Harmon JM. Positive regulation of the glucocorticoid receptor in human T-cells sensitive to the cytolytic effects of glucocorticoids. J Biol Chem. 1988;263:12044–12048.
   PubMed Web of Science ®Google Scholar
• Denton RR, Eisen LP, Elsasser MS, et al. Differential autoregulation of glucocorticoid receptor expression in human T- and B-cell lines. Endocrinology. 1993;133:248–256.
   PubMed Web of Science ®Google Scholar
• Schmidt S, Rainer J, Ploner C, et al. Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ. 2004;11:S45–S55.
   PubMed Web of Science ®Google Scholar
• Kofler R. The molecular basis of glucocorticoid-induced apoptosis of lymphoblastic leukemia cells. Histochem Cell Biol. 2000;114:1–7.
   PubMed Web of Science ®Google Scholar
• Schmidt S, Irving JA, Minto L, et al. Glucocorticoid resistance in two key models of acute lymphoblastic leukemia occurs at the level of the glucocorticoid receptor. FASEB J. 2006;20:2600–2602.
   PubMed Web of Science ®Google Scholar
• Wei G, Twomey D, Lamb J, et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell. 2006;10:331–342.
   PubMed Web of Science ®Google Scholar
• Gu L, Zhou C, Liu H, et al. Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis. J Exp Clin Cancer Res. 2010;29:150.
   PubMed Web of Science ®Google Scholar
• Guo X, Zhou CY, Li Q, et al. Rapamycin sensitizes glucocorticoid resistant acute lymphoblastic leukemia CEM-C1 cells to dexamethasone induced apoptosis through both mTOR suppression and up-regulation and activation of glucocorticoid receptor. Biomed Environ Sci. 2013;26:371–381.
   PubMed Web of Science ®Google Scholar